<a href="https://www.fiercebiotech.com/biotech/roche-takes-leap-faith-20m-bet-c4ts-antibody-targeted-protein-degraders" hreflang="en">Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders</a>
fiercebiotech.com·Apr 8, 2026
Roche has partnered with C4 Therapeutics, paying $20 million upfront and committing over $1 billion in potential milestones, to collaborate on two oncology targets in the degrader-antibody conjugate space.
Roche's significant investment in the degrader-antibody conjugate space signals a strategic focus on innovative oncology treatments, highlighting an opportunity for professionals in healthtech and biotech to explore partnerships and advancements in targeted cancer therapies. This move underscores the potential for substantial growth and collaboration in the evolving field of precision medicine and drug discovery.